Skip to Main Content

Paper Details

CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
J Neurosurg
22
2016
*2, *3, *8, CES1, CES1 G143E, CYP2C19, CYP2C19 (, CYP2C19 LOF alleles, CYP2C19 loss of function (LOF) alleles, CYP2C19 loss of function (LOF) alleles *2, *3, and *8, CYP2C19 variants, CYP2C19*2, (*)3, (*)8, CYP2C19*2, (*)3, (*)8, (*)17, DNA sample, G143E, ICAD, LOF allele, SNPs, TIA, aspirin, clopidogrel, intracranial atherosclerotic disease, myocardial infarction, patients, single-nucleotide polymorphisms, stroke, transient ischemic attack, wild
Author NameAffiliation
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida
Ben BurkleyDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida
Taimour Y LangaeeDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida
Jay Mocco
Jay Mocco
Christian M Shaffer
Joshua C Denny
Murray H BrilliantCenter for Human Genetics Research and.
Terrie KitchnerCenter for Human Genetics Research and.
James G LinnemanBiomedical Informatics Research Center, Marshfield Clinic Research Foundation
Dan M Roden
Dan M RodenVanderbilt University School of Medicine
Julie A JohnsonCollege of Medicine
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida
  • 1 - 15

Datasets

Release 1.2